UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Boston Scientific Boston Scientific (NYSE: BSX) saw its net income expand by $0.9 billion or 145% y-o-y to $1.6 billion in 2023. This can primarily be attributed to an expansion of its operating margin and lower taxes. In this note, ...

公司业绩 - 波士顿科学公司在过去一年中股价上涨了40.7%，超过了行业平均增长率[1] - 公司在过去五年中实现了7.3%的盈利增长，超过了行业的增长率[2] - 波士顿科学公司的长期预期增长率为12.5%，高于行业平均增长率[2] 市场表现 - 公司在MedSurg领域市场份额增长迅速，股价呈上升趋势[3] - 公司在新兴市场扩展业务，受到投资者乐观情绪的支持[5] - 公司在新兴市场的净销售额在年度基础上表现强劲[6] 业务表现 - 公司在MedSurg领域内持续快速恢复，特别是内窥镜业务受益于全球需求[7] - 公司在2024年第一季度实现了强劲的有机增长贡献，内窥镜在多个地区表现强劲[8] - 公司在所有地理区域的传统业务中实现了有机销售的强劲反弹[9] 风险因素 - 公司40%的销售来自国际市场，对货币波动高度敏感[10] - 医疗设备市场竞争激烈，公司面临来自多个竞争对手的挑战[11]

Boston Scientific Corporation (BSX) recently presented favorable six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System — the first modular cardiac rhythm management system that consists of the EMBLEM Subcutaneous Implantable Defibrillator or S-ICD System and the EMPOWER Leadless Pacemaker. The findings were concurrently published in the New England Journal of Medicine and presented at the Heart Rhythm Society's annual meeting, Heart Rhythm 2024. The recent development will ...

Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and t ...

文章核心观点 - 分析师推荐对股票价格有影响,但其可靠性存在问题 [1][4][5][6] - 分析师倾向于给予积极偏好的评级,与普通投资者利益不一致 [5][6][10][11] - 使用Zacks Rank评级系统可能更有效地预测股价走势 [7][11][12][13][14][15][16] 公司概况 - 波士顿科学公司(Boston Scientific)目前的平均券商评级(ABR)为1.29,介于"强烈买入"和"买入"之间 [2][3] - 19家券商给予"强烈买入"评级,3家给予"买入"评级,占总评级的79.2%和12.5% [3] 行业分析 - 分析师的评级往往存在积极偏好,给予"强烈买入"的评级远多于"强烈卖出" [5][10][11] - 使用Zacks Rank评级系统可能更有效地预测股价走势,因为它基于盈利预测修正 [7][11][12][13][14][15][16] - 与ABR不同,Zacks Rank更及时反映公司业绩变化 [13]

文章核心观点 - 波士顿科学公司(Boston Scientific)在所有细分市场均持续增加市场份额 [1] - 公司最近获得的新监管批准和收购案有利于其长期增长 [1] - 公司目前被评为"买入"评级 [1] 行业和公司研究 医疗器械业务 - 公司的内窥镜业务在全球范围内需求强劲,带动了消化道和肺部治疗选择的增长 [2] - 公司的胆道、止血、单次使用成像和金属支架业务也在持续增长 [2] 泌尿系统业务 - 公司的泌尿系统业务在全球范围内持续扩张市场份额 [3] - 其石头管理业务增长强劲,主要得益于LithoVue单次使用数字柔性输尿管镜系统 [3] 神经调节业务 - 公司的疼痛业务持续增长,主要得益于脊髓刺激疗法(SCS)的强劲表现 [4] - SCS业务受益于Alpha组合的创新以及支持患者激活的认知套件数字工具 [4] 结构性心脏业务 - 公司的WATCHMAN左心耳封堵装置表现强劲,成为非药物性替代口服抗凝剂的领先设备 [5] - 下一代WATCHMAN FLX在欧洲市场正在快速渗透 [5] 收购带来的潜力 - 公司最近的收购为其带来了众多具有巨大潜力的产品(尽管大部分仍在开发中) [6] - 2024年3月收购了B. Braun的内腔负压治疗组合 [7] - 2023年12月收购了Axonics,以扩大其在泌尿系统领域的差异化技术组合 [7] 挑战与风险 - 宏观经济环境恶化,如地缘政治压力、供应链和劳动力市场中断等,给公司业务带来挑战 [8] - 国际冲突加剧了网络安全风险 [8] - 金融市场动荡和商品服务价格大幅波动,压缩了公司的盈利能力 [8] - 持续的宏观压力可能使公司难以控制其运营费用 [8] - 2024年第一季度,公司产品销售成本上升16.3%,毛利率下降67个基点,销售费用和管理费用上升12.3% [9]

MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has more than 25 years of clinical and business leadership experience, most recently serving as a partner at Morgan Health focused on improving the quality, affordability and equity of health care. Prior to that, Dr. Pegus was executive vice president of Health & Wellness at Walmart, president of Consumer Soluti ...

It’s not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices. With that in mind, the savvy investor will want to focus on Needham price targets to steer them out of the current chaos. Needham price targets can be a reliable guide to steer you through turbulence. Needham ratings become doubly important when the market is down, with investors looking to identify resilient stocks or those with strong recover ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation or ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Boston Scientific (BSX) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Boston Scientific is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the i ...